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Project Goals

Plausible Mechanism of Action of Gabapentin (3)

1. Compounded formulations for potency assessment were
purchased from 2 compounding pharmacies. 2 samples from each
(one at 50mg/mL , the other at 100 mg/mL).
2. Standard gabapentin (Sigma Aldrich) was acquired and a series of
8 serial dilutions were made ranging in concentration from
1mg/mL to 10 mg/mL.
3. The mobile phase for the HPLC was a methanol – acetonitrile –
potassium dihydrogen phosphate (pH5.2; 0.028 M) (25:10:65,
v/v) solution. The HPLC was set to collect data at 210 nm and the
flow rate was set to 1.00 mL/min which was set to remain
consistent throughout data collection.
4. Aliquots of 25 µL of each of the eight serial dilutions were loaded
into the HPLC and the area under the curve of the peak was
collected.
5. Standard equation was formed and used to determine
concentration following HPLC of experimental groups keeping
HPLC parameters the same.

1. To provide a review of the literature on veterinary compounding,
its need and limitations.
2. To research the use of gabapentin to manage feline pain and study
its metabolic and pharmacokinetic profile.
3. To quantify the concentration of gabapentin in compounded
formulations of the drug using HPLC.

Chemical structure of
gabapentin (Image from Sigma-Aldrich)
Brand Name: Neurontin

Compounding: the preparation, mixing, assembling,
packaging, or labeling of a drug completed by a pharmacist
or physician (National Association of Boards of Pharmacy).

*Due to COID-19 restrictions, not enough data was generated prior to
this conference to be presented.

USA Pharmacopeia Guidelines on Compounded
Formulations: a formulation must contain 90% to 110% of
the labeled drug content in order to be acceptable. E.g.,
labeled drug content = 50 mg/mL so acceptable
concentration range would be 45-55 mg/mL

Conclusions and Future Directions
• More widespread studies investigating potency of compounded
veterinary formulations.
• Push for more widespread oversight and regulation that matches
the frequency of compounding to discourage malpractice.
• Species-specific pharmacological research in order to fill
knowledge gaps and create species-specific models for treating
various disorders.
• Regarding gabapentin specifically, studies aimed with finding the
optimal plasma concentrations of the drug in cats and dogs
are needed.

Pharmaceutical Compounding in Veterinary Medicine
Compounding as an essential practice (1):

• Number of species to be treated
• Number of ailments to be addressed
• Minimal financial incentive for pharmaceutical companies to
pursue veterinary drug approval
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Compounding

Burton et al., 2016 (2):
• Reduced frequency of neutropenia in canines taking
compounded lomustine
• 21 dogs receiving FDA approved lomustine vs 16
dogs receiving compounded version. 71% vs 25%
neutropenic, respectively.
• Follow-up study: samples of compounded lomustine
from 5 compounding pharmacies acquired and
potency was analyzed using HPLC with UV
detection.
• Samples ranged in potency from 50 to 115% . Only 1
pharmacy out of 5 provided appropriately
compounded lomustine.

Experimental Approach to Analyzing Potency

Pharmacokinetics
of Gabapentin

CMAX (ug/mL) TMAX (hours)

Felines (4)

12.42

1.05

Canines (5)

8.54

1.30
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